GlaxoSmithKline reported a 15% rise in sales to £6.67 billion in the third quarter which ended on September 30.

Andrew Witty, chief executive of GSK, said the performance of consumer healthcare is especially impressive as the global market only grew 1.5%. In the next quarter GSK expects to see further growth especially in sales of its influenza products including swine flu vaccine, Relenza.

In addition, sales of Reckitt Benckiser also saw sales climbing 15% to £1.9 billion driven by “significant” investment in media, marketing and new products.

via Marketing Week